The major focus of the Anderson Lab is the development, evaluation and application of radiopharmaceuticals containing metal radionuclides for diagnostic imaging and radiotherapy. We are particularly interested in 64Cu (T1/2 = 12.7 hours), in large part because it emits beta+ particles for positron emission tomography (PET) imaging and beta- particles for targeted radiotherapy. We are also investigating 68Ga (T1/2 = 68 min) as a generator-produced positron-emitting radionuclide. The agents we are studying are 64Cu- and 68Ga-labeled chelator-peptide and monoclonal antibody conjugates for imaging and/or therapy of various types of cancer. One area of investigation in our laboratory is the development of radiolabeled alpha vs. beta 3 integrin ligands as PET agents for imaging bone metastasis. We have developed one agent, 64Cu-CB-TE2A-c(RGDyK), that specifically binds to alpha vs. beta 3 integrin in osteoclasts, which are bone resorbing cells that are present in high concentration in osteolytic bone lesions. This agent may be able to earlier detect painful, debilitating bone lesions associated with breast cancer, and multiple myeloma, as well as be used to determine early response to treatment of bone lesions associated with these diseases. Another area of focus for our lab is investigating imaging agents that target cell types, other than tumor cells, involved in cancer metastasis. For example, we are targeting integrin alpha 4 beta 1 as a marker of bone marrow derived cells that home to sites of metastasis prior to tumor cells as part of the pre-metastatic niche. We are also investigating immune cell types, such as macrophages, neutrophils and T-cells and their role in cancer and other diseases.